Contemporary H3N2 influenza viruses have a glycosylation site that alters binding of antibodies elicited by egg-adapted vaccine strains

Proceedings of the National Academy of Sciences of the United States of America

Volumn 114, Issue 47, 2017, Pages 12578-12583

  Zost, Seth J ^a   Parkhouse, Kaela ^a   Gumina, Megan E ^a   Kim, Kangchon ^b   Perez, Sebastian Diaz ^a   Wilson, Patrick C ^b   Treanor, John J ^c   Sant, Andrea J ^c   Cobey, Sarah ^b   Hensley, Scott E ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

Antibody; Hemagglutinin; Influenza; Vaccine

Indexed keywords

INFLUENZA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; MONOCLONAL ANTIBODY; VIRUS GLYCOPROTEIN; VIRUS ANTIBODY; VIRUS ANTIGEN;

ADAPTATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGEN BINDING; ANTIGENICITY; ARTICLE; CONTROLLED STUDY; EGG; GLYCOSYLATION; HUMAN; INFLUENZA A (H3N2); INFLUENZA A VIRUS (H3N2); INFLUENZA VACCINATION; MUSTELA PUTORIUS FURO; NONHUMAN; PRIORITY JOURNAL; VIRUS MUTATION; VIRUS STRAIN; ANIMAL; CHEMISTRY; CHICKEN; GENETICS; IMMUNOLOGY; INFLUENZA; METABOLISM; MUTATION; OVUM; SERODIAGNOSIS; VACCINE IMMUNOGENICITY; VIROLOGY;

ANIMALS; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; CHICKENS; FERRETS; GLYCOSYLATION; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HUMANS; IMMUNOGENICITY, VACCINE; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MUTATION; NEUTRALIZATION TESTS; OVUM;

EID: 85034580209     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1712377114     Document Type: Article

References (48)

1. Yewdell JW (2011) Viva la revolución: Rethinking influenza a virus antigenic drift. Curr Opin Virol 1:177–183.
2. Belongia EA, et al. (2016) Variable influenza vaccine effectiveness by subtype: A systematic review and meta-analysis of test-negative design studies. Lancet Infect Dis 16:942–951.
3. Carrat F, Flahault A (2007) Influenza vaccine: The challenge of antigenic drift. Vaccine 25:6852–6862.
4. Schultz-Cherry S, Jones JC (2010) Influenza vaccines: The good, the bad, and the eggs. Adv Virus Res 77:63–84.
5. Krammer F, Palese P, Steel J (2015) Advances in universal influenza virus vaccine design and antibody mediated therapies based on conserved regions of the hemagglutinin. Curr Top Microbiol Immunol 386:301–321.
6. Koel BF, et al. (2013) Substitutions near the receptor binding site determine major antigenic change during influenza virus evolution. Science 342:976–979.
7. Smith DJ, et al. (2004) Mapping the antigenic and genetic evolution of influenza virus. Science 305:371–376.
8. Skehel JJ, et al. (1984) A carbohydrate side chain on hemagglutinins of Hong Kong influenza viruses inhibits recognition by a monoclonal antibody. Proc Natl Acad Sci USA 81:1779–1783.
9. Wrigley NG, et al. (1983) Electron microscopy of influenza haemagglutinin-monoclonal antibody complexes. Virology 131:308–314.
10. Abe Y, et al. (2004) Effect of the addition of oligosaccharides on the biological activities and antigenicity of influenza A/H3N2 virus hemagglutinin. J Virol 78:9605–9611.
11. Das SR, et al. (2011) Fitness costs limit influenza A virus hemagglutinin glycosylation as an immune evasion strategy. Proc Natl Acad Sci USA 108:E1417–E1422.
12. Wei CJ, et al. (2010) Cross-neutralization of 1918 and 2009 influenza viruses: Role of glycans in viral evolution and vaccine design. Sci Transl Med 2:24ra21.
13. Medina RA, et al. (2013) Glycosylations in the globular head of the hemagglutinin protein modulate the virulence and antigenic properties of the H1N1 influenza viruses. Sci Transl Med 5:187ra70.
14. Cherry JL, Lipman DJ, Nikolskaya A, Wolf YI (2009) Evolutionary dynamics of N-glycosylation sites of influenza virus hemagglutinin. PLoS Curr 1:RRN1001.
15. Zimmerman RK, et al.; US Flu VE Investigators (2016) 2014–2015 Influenza vaccine effectiveness in the United States by vaccine type. Clin Infect Dis 63:1564–1573.
16. D’Mello T, et al.; Centers for Disease Control and Prevention (CDC) (2015) Update: Influenza activity—United States, September 28, 2014–February 21, 2015. MMWR Morb Mortal Wkly Rep 64:206–212.
17. Chambers BS, Parkhouse K, Ross TM, Alby K, Hensley SE (2015) Identification of hemagglutinin residues responsible for H3N2 antigenic drift during the 2014–2015 influenza season. Cell Rep 12:1–6.
18. Flannery B, et al. (2016) Enhanced genetic characterization of influenza A(H3N2) viruses and vaccine effectiveness by genetic group, 2014–2015. J Infect Dis 214:1010–1019.
19. Anonymous (2016) Recommended composition of influenza virus vaccines for use in the 2016–2017 northern hemisphere influenza season. Wkly Epidemiol Rec 91:121–132.
20. Flannery B, et al. (2017) Interim estimates of 2016–17 seasonal influenza vaccine effectiveness—United States, February 2017. MMWR Morb Mortal Wkly Rep 66:167–171.
21. Lin Y, et al. (2017) The characteristics and antigenic properties of recently emerged subclade 3C.3a and 3C.2a human influenza A(H3N2) viruses passaged in MDCK cells. Influenza Other Respir Viruses 11:263–274.
22. Thompson MG, et al. (2016) Effects of repeated annual inactivated influenza vaccination among healthcare personnel on serum hemagglutinin inhibition antibody response to A/Perth/16/2009 (H3N2)-like virus during 2010–11. Vaccine 34:981–988.
23. Leung VKY, et al. (2017) Influenza vaccination responses: Evaluating impact of repeat vaccination among health care workers. Vaccine 35:2558–2568.
24. Huang KA, Chang SC, Huang YC, Chiu CH, Lin TY (2017) Antibody responses to trivalent inactivated influenza vaccine in health care personnel previously vaccinated and vaccinated for the first time. Sci Rep 7:40027.
25. McLean HQ, et al. (2014) Impact of repeated vaccination on vaccine effectiveness against influenza A(H3N2) and B during 8 seasons. Clin Infect Dis 59:1375–1385.
26. Ohmit SE, et al. (2013) Influenza vaccine effectiveness in the community and the household. Clin Infect Dis 56:1363–1369.
27. Skowronski DM, et al. (2016) A perfect storm: Impact of genomic variation and serial vaccination on low influenza vaccine effectiveness during the 2014–2015 season. Clin Infect Dis 63:21–32.
28. Hensley SE, et al. (2009) Hemagglutinin receptor binding avidity drives influenza A virus antigenic drift. Science 326:734–736.
29. Li Y, et al. (2013) Single hemagglutinin mutations that alter both antigenicity and receptor binding avidity influence influenza virus antigenic clustering. J Virol 87: 9904–9910.
30. Gambaryan AS, Robertson JS, Matrosovich MN (1999) Effects of egg-adaptation on the receptor-binding properties of human influenza A and B viruses. Virology 258: 232–239.
31. Gambaryan AS, et al. (1998) Effects of host-dependent glycosylation of hemagglutinin on receptor-binding properties on H1N1 human influenza A virus grown in MDCK cells and in embryonated eggs. Virology 247:170–177.
32. Kilbourne ED (1978) Genetic dimorphism in influenza viruses: Characterization of stably associated hemagglutinin mutants differing in antigenicity and biological properties. Proc Natl Acad Sci USA 75:6258–6262.
33. Schild GC, Oxford JS, de Jong JC, Webster RG (1983) Evidence for host-cell selection of influenza virus antigenic variants. Nature 303:706–709.
34. Katz JM, Webster RG (1989) Efficacy of inactivated influenza A virus (H3N2) vaccines grown in mammalian cells or embryonated eggs. J Infect Dis 160:191–198.
35. Kilbourne ED, et al. (1993) Influenza A virus haemagglutinin polymorphism: Pleio-tropic antigenic variants of A/Shanghai/11/87 (H3N2) virus selected as high yield re-assortants. J Gen Virol 74:1311–1316.
36. Meyer WJ, et al. (1993) Influence of host cell-mediated variation on the international surveillance of influenza A (H3N2) viruses. Virology 196:130–137.
37. Chen Z, Zhou H, Jin H (2010) The impact of key amino acid substitutions in the hemagglutinin of influenza A (H3N2) viruses on vaccine production and antibody response. Vaccine 28:4079–4085.
38. Skowronski DM, et al. (2014) Low 2012–13 influenza vaccine effectiveness associated with mutation in the egg-adapted H3N2 vaccine strain not antigenic drift in circulating viruses. PLoS One 9:e92153.
39. Cobey S, et al. (2017) Despite egg-adaptive mutations, the 2012–13 H3N2 influenza vaccine induced comparable antibody titers to the intended strain. bioRxiv:10.1101/158550.
40. An Y, et al. (2013) Comparative glycomics analysis of influenza hemagglutinin (H5N1) produced in vaccine relevant cell platforms. J Proteome Res 12:3707–3720.
41. Dunkle LM, et al.; PSC12 Study Team (2017) Efficacy of recombinant influenza vaccine in adults 50 years of age or older. N Engl J Med 376:2427–2436.
42. Cobey S, Hensley SE (2017) Immune history and influenza virus susceptibility. Curr Opin Virol 22:105–111.
43. Li GM, et al. (2012) Pandemic H1N1 influenza vaccine induces a recall response in humans that favors broadly cross-reactive memory B cells. Proc Natl Acad Sci USA 109:9047–9052.
44. Linderman SL, et al. (2014) Potential antigenic explanation for atypical H1N1 infections among middle-aged adults during the 2013-2014 influenza season. Proc Natl Acad Sci USA 111:15798–15803.
45. Li Y, et al. (2013) Immune history shapes specificity of pandemic H1N1 influenza antibody responses. J Exp Med 210:1493–1500.
46. Wrammert J, et al. (2011) Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. J Exp Med 208:181–193.
47. Gostic KM, Ambrose M, Worobey M, Lloyd-Smith JO (2016) Potent protection against H5N1 and H7N9 influenza via childhood hemagglutinin imprinting. Science 354:722–726.
48. Henry Dunand CJ, et al. (2015) Preexisting human antibodies neutralize recently emerged H7N9 influenza strains. J Clin Invest 125:1255–1268.